297:. James Abell has held the post of chief financial officer since at least 2001. The company also has a board of directors, which consisted of two members in 2016, Stephen Bunting and Theodore Clark. Bunting had been a managing partner from 2002 to at least 2014, having joined Abingworth in 1987 after leaving Rothschild with Leathers. By 2014, Bunting had been involved in the establishment each of the ten (at that time) of the company's life science investment funds.
29:
162:
and Hon. Anthony
Montagu. Abingworth had initially sought to extend its investments into the biotechnology industry in the late 1980s, and has subsequently been investing in life science and healthcare services companies since at least 2001, and had expanded to include information technology firm
225:
The firm created its biotech investment arm in 1987. Among the first investments was in
Immunology Ltd, which was later renamed to Cantab Pharmaceuticals. In 2000, the company joined several others in providing funding for Oxagen. In the early 2000s, the firm invested in and saw forward to
206:
with particular investment targets in mind. For instance, the "Bioventures VI" fund was "closed" in March 2014, having accrued $ 375 million, reportedly exceeding the "target" for the fund. A key element in the firm's investment strategy is the
256:
In 2013, the firm invested in
Effector Therapeutics. It also, in January 2013, set up Avillion Group Partners, a clinical phase III co-development accelerator, with Massachusetts-based Clarus Ventures. Following from this, Avillion partnered with
708:
599:
698:
280:
As of 2001, Abingworth had less than 10 employees. and the company managed $ 300 million across several funds and had provided capital to sixty life science companies..
651:
703:
337:
461:
713:
718:
723:
546:
413:
572:
506:
246:. In the Algeta case, this was the very first of the firm's venture investments in public equities, dating to February 2009.
432:
345:
652:"Carlyle vaults into biotech investing, buying Abingworth and launching a new company aimed at pivotal leaps"
227:
211:
which signifies the acquisition of or initial public offering by a company in which the firm has invested.
183:
625:
179:
309:. At the time of the acquisition, Abingworth had approximately $ 2 billion in assets under management.
294:
214:
Prior to 1987, Abingworth had made investments, considered by 2016 to have been successful, in
409:
306:
167:
117:
287:
219:
249:
In 2013, the firm realised an exit from investment in
Syntaxin Ltd when it was acquired by
231:
462:"Carlyle's acquisition of Abingworth brings $ 2 billion to fuel life science investments"
290:, Timothy J. Haines and Kurt von Emster. and the firm had grown to over 20 employees.
692:
269:
514:
283:
By 2014, the managed value of one of the firm's ten funds was $ 375 million.
159:
76:
436:
406:
Science, the State and the City: Britain's
Struggle to Succeed in Biotechnology
367:
215:
28:
154:) is a transatlantic bioscience investment firm founded in 1973 by a pair of
191:
182:
as of 2001. By 2016, the Palo Alto office had been replaced by an office in
600:"How HealthCap, Abingworth apply lessons from successful Algeta investment"
547:"With $ 375M in the bank, VC Abingworth hunts for a few promising biotechs"
262:
243:
293:"Special partner" David Leathers joined the firm in 1987, having left
178:
In addition to its base in London, the company had a second office in
258:
235:
187:
155:
93:
234:. The firm has also provided funding to support the acquisition of
250:
239:
507:"Abingworth Closes on Its 10th Life Sci Fund – an Upsized $ 375M"
202:
The company's investment strategy involves the establishment of
681:
134:
573:"Bayer to Acquire Drug Maker Algeta in $ 2.9 Billion Deal"
435:. New England Venture Capital Association. Archived from
230:
a number of firms, including
Dicerna Pharmaceuticals and
186:, and an additional offices had been established in
129:
104:
88:
69:
51:
43:
35:
598:
8:
404:Owen, Geoffrey; Hopkins, Michael M. (2016).
21:
709:Venture capital firms of the United Kingdom
305:In August 2022, Abingworth was acquired by
166:In August 2022, Abingworth was acquired by
699:Companies based in the City of Westminster
272:companies, Avedro and Gensight Biologics.
27:
20:
318:
704:British companies established in 1973
7:
597:Hansen, Stephen (10 February 2014).
540:
538:
536:
534:
532:
501:
499:
497:
495:
493:
491:
489:
487:
485:
483:
456:
454:
427:
425:
399:
397:
395:
393:
391:
389:
387:
385:
332:
330:
328:
326:
324:
322:
626:"Algeta raises $ 35M in a placing"
545:Garde, Damian (28 February 2014).
268:In 2014, the firm invested in two
14:
261:on a label expansion effort for
571:Bray, Chad (19 December 2013).
714:1973 establishments in England
525:– via Highbeam Research.
513:. 3 March 2014. Archived from
1:
719:2022 mergers and acquisitions
368:"Abingworth LLP Top Holdings"
724:The Carlyle Group companies
408:. Oxford University Press.
344:. Bloomberg. Archived from
342:Private Company Information
286:As of 2016, there were two
57:; 51 years ago
740:
242:and Avila Therapeutics by
152:Abingworth Management Ltd.
47:Bioscience investment firm
39:Abingworth Management Ltd
26:
228:initial public offering
163:investments by 2016.
81:Hon. Anthony Montagu
16:Venture capital firm
517:on 18 November 2018
348:on 24 November 2016
23:
632:. 19 February 2009
307:The Carlyle Group
288:managing partners
276:Corporate details
168:The Carlyle Group
145:
144:
118:The Carlyle Group
731:
685:
684:
682:Official website
667:
666:
664:
662:
648:
642:
641:
639:
637:
630:Science|Business
622:
616:
615:
613:
611:
602:
594:
588:
587:
585:
583:
568:
562:
561:
559:
557:
542:
527:
526:
524:
522:
503:
478:
477:
475:
473:
458:
449:
448:
446:
444:
439:on 15 April 2016
429:
420:
419:
401:
380:
379:
377:
375:
364:
358:
357:
355:
353:
338:"Abingworth LLP"
334:
220:Silicon Graphics
141:
138:
136:
122:
114:
65:
63:
58:
31:
24:
739:
738:
734:
733:
732:
730:
729:
728:
689:
688:
680:
679:
676:
671:
670:
660:
658:
650:
649:
645:
635:
633:
624:
623:
619:
609:
607:
596:
595:
591:
581:
579:
570:
569:
565:
555:
553:
544:
543:
530:
520:
518:
505:
504:
481:
471:
469:
468:. 12 April 2022
460:
459:
452:
442:
440:
431:
430:
423:
416:
403:
402:
383:
373:
371:
366:
365:
361:
351:
349:
336:
335:
320:
315:
303:
278:
232:Clovis Oncology
200:
176:
133:
125:
120:
112:
100:
96:
84:
61:
59:
56:
17:
12:
11:
5:
737:
735:
727:
726:
721:
716:
711:
706:
701:
691:
690:
687:
686:
675:
674:External links
672:
669:
668:
656:Endpoints News
643:
617:
589:
563:
528:
511:Bioworld Today
479:
466:Fierce Biotech
450:
421:
414:
381:
370:. Whale Wisdom
359:
317:
316:
314:
311:
302:
299:
277:
274:
199:
196:
175:
172:
158:stockbrokers,
148:Abingworth LLP
143:
142:
131:
127:
126:
124:
123:
121:(2022–present)
115:
108:
106:
102:
101:
98:
92:
90:
86:
85:
83:
82:
79:
73:
71:
67:
66:
53:
49:
48:
45:
41:
40:
37:
33:
32:
22:Abingworth LLP
15:
13:
10:
9:
6:
4:
3:
2:
736:
725:
722:
720:
717:
715:
712:
710:
707:
705:
702:
700:
697:
696:
694:
683:
678:
677:
673:
657:
653:
647:
644:
631:
627:
621:
618:
606:
601:
593:
590:
578:
574:
567:
564:
552:
551:FierceBiotech
548:
541:
539:
537:
535:
533:
529:
516:
512:
508:
502:
500:
498:
496:
494:
492:
490:
488:
486:
484:
480:
467:
463:
457:
455:
451:
438:
434:
428:
426:
422:
417:
415:9780191043888
411:
407:
400:
398:
396:
394:
392:
390:
388:
386:
382:
369:
363:
360:
347:
343:
339:
333:
331:
329:
327:
325:
323:
319:
312:
310:
308:
300:
298:
296:
291:
289:
284:
281:
275:
273:
271:
266:
264:
260:
254:
252:
247:
245:
241:
237:
233:
229:
223:
221:
217:
212:
210:
205:
197:
195:
193:
189:
185:
181:
173:
171:
169:
164:
161:
157:
153:
149:
140:
132:
128:
119:
116:
110:
109:
107:
103:
95:
91:
87:
80:
78:
75:
74:
72:
68:
54:
50:
46:
42:
38:
34:
30:
25:
19:
659:. Retrieved
655:
646:
634:. Retrieved
629:
620:
608:. Retrieved
604:
592:
580:. Retrieved
576:
566:
554:. Retrieved
550:
519:. Retrieved
515:the original
510:
470:. Retrieved
465:
441:. Retrieved
437:the original
433:"Abingworth"
405:
372:. Retrieved
362:
350:. Retrieved
346:the original
341:
304:
292:
285:
282:
279:
267:
255:
248:
224:
213:
208:
203:
201:
177:
165:
151:
147:
146:
111:Independent
89:Headquarters
18:
661:22 February
636:24 November
610:24 November
582:24 November
556:22 November
521:24 November
472:22 February
443:26 November
374:26 November
352:22 November
301:Acquisition
198:Investments
160:Peter Dicks
137:.abingworth
113:(1973–2022)
77:Peter Dicks
693:Categories
605:BioCentury
313:References
295:Rothschild
270:ophthalmic
184:Menlo Park
150:(formerly
192:Cambridge
180:Palo Alto
577:DealBook
70:Founders
44:Industry
36:Formerly
263:Bosulif
244:Celgene
174:Offices
130:Website
60: (
52:Founded
412:
259:Pfizer
236:Algeta
188:Boston
156:London
94:London
251:Ipsen
240:Bayer
216:Apple
209:exit,
204:funds
105:Owner
663:2023
638:2016
612:2016
584:2016
558:2016
523:2016
474:2023
445:2016
410:ISBN
376:2016
354:2016
253:SA.
218:and
190:and
139:.com
62:1973
55:1973
238:by
135:www
695::
654:.
628:.
603:.
575:.
549:.
531:^
509:.
482:^
464:.
453:^
424:^
384:^
340:.
321:^
265:.
222:.
194:.
170:.
99:UK
97:,
665:.
640:.
614:.
586:.
560:.
476:.
447:.
418:.
378:.
356:.
64:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
